NCT00022620

Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer

Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: European Organisation for Research and Treatment of Cancer - EORTC · Network
• Sex: Female
• Age: 75 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer.

Detailed description

OBJECTIVES: * Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma. * Determine the objective response and duration of response in patients treated with this regimen. * Determine the acute side effects of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 12 weeks. PROJECTED ACCRUAL: Approximately 16-29 patients will be accrued for this study.

Conditions

• Endometrial Cancer

Interventions

Type	Name	Description
DRUG	paclitaxel

Timeline

• Start date: 2001-06-01
• Primary completion: 2002-10-01
• First posted: 2003-01-27
• Last updated: 2012-09-24

Locations

8 sites across 6 countries: Austria, Belgium, Italy, Portugal, Spain, United Kingdom